1. INTRODUCTION {#sec1}
===============

Type 2 diabetes (T2D) is an epidemic disease, affecting the health of millions of subjects worldwide \[[@r1]\]. Accordingly, glucose metabolism disorders facilitate profound disturbances in the metabolism of lipids and amino acids and inflict long-lasting injury effects on different tissues and organs \[[@r2]\]. The regulation of insulin sensitivity is a critical issue in maintaining glucose homeostasis and alleviating both T2D and obesity \[[@r3]\]. High-density lipoprotein (HDL) can regulate glucose homeostasis by enhancing insulin sensitivity and increasing insulin synthesis and secretion \[[@r4]-[@r8]\]. Apolipoprotein M (ApoM) is a member of lipocalin superfamily that is associated with the formation of pre-β HDL \[[@r9], [@r10]\]. This lipoprotein was discovered approximately 20 years ago \[[@r11]\]. However, the function and regulating mechanism of apoM in glucose homeostasis have not been fully understood . The association between apoM and glucose metabolism has been previously investigated in several research studies \[[@r12]-[@r14]\]. Certain SNPs of the *APOM* gene, such as the T-778C have been shown to be associated with type 1 and 2 Mellitus \[[@r15]\]. ApoM serum levels have also been shown to function as a marker for maturity-onset diabetes of the young 3 (MODY3) \[[@r16]\], which is characterized by mutations in the *hepatocyte nuclear factor-1 α (HNF-1α)* gene. In addition, it has been shown that *Hnf-1α^-/-^* mice exhibit undetectable plasma apoM levels \[[@r17]\]. However, the precise underlying mechanisms for these epidemiological associations have not been elucidated yet.

A previous study has suggested that higher plasma apoM concentration is consistent with higher insulin sensitivity \[[@r18]\]. *ApoM* gene expression in obese mice is markedly decreased \[[@r19]\], and weight-reducing diets can increase *ApoM* gene expression and secretion in adipose tissues \[[@r18]\]. Notably, apoM has been deemed an important component of rare adipokines associated with healthy metabolic status \[[@r18]\]. *APOM* gene polymorphism is also related to the metabolism of HDL in obese Korean male adults \[[@r20]\]. The aforementioned studies have shown that apoM may play a causative role in insulin sensitivity. To comprehensively understand the role of insulin and examine the potential mechanism of action in lipid disorders, a thorough investigation of the signaling cascades of insulin is required. AKT is the main pathway involved in insulin-associated lipid and glucose metabolism \[[@r21], [@r22]\]. Under normal conditions, insulin activates the AKT signaling pathway, which finally leads to an increase in glucose utilization and a decrease in gluconeogenesis in muscle or adipose tissues \[[@r23], [@r24]\]. Impaired AKT signaling is one of the main causes of insulin resistance, which in turn exacerbates AKT signaling \[[@r25]\]. It is reported that apoM together with sphingosine-1-phosphate inhibits oxidatively modified low-density lipoprotein induced inflammation by activating the AKT pathway \[[@r26], [@r27]\]. A previous study also demonstrated that overexpressing apoM might promote activation of AKT signaling pathways in lung cancer cells \[[@r28]\]. Therefore, it was supposed that apoM might improve insulin sensitivity by enhancing AKT activation.

Briefly, glucose metabolism and the differential genes were measured in the liver tissues of *ApoM^-/-^* mice who were fed a high-fat diet by means of metabonomic approach, microarray and bioinformatic analysis. Furthermore, the insulin sensitivity of *ApoM^-/-^* and WT mice was compared with the phosphorylation levels of AKT following insulin stimulation in different tissues.

2. Materials and Methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

*ApoM^-/-^* mice (C57BL/6J) were employed at the animal research institute of the Nanjing University (Jiangsu) \[[@r29]\]. The genotypes of parental mice and their offsprings were analyzed by polymerase chain reaction as described previously \[[@r30]\]. The conditions for a regular and stress-free life period were provided, including a moderate temperature (20-25°C), suitable relative humidity (55-60%), and standard light cycle (12-h light/dark) in a pathogen-free animal facility. These mice were bred at the Animal Facility of the Soochow University. The 6-week-old *ApoM^-/-^*(n=22) and WT(n=21) mice were fed a high-fat diet (10% lard, 10% milk, 20% cholesterol) for 34 weeks and subjected to a 5 h fasting period prior to sacrifice \[[@r31]\]. Blood glucose level detection and insulin tolerance test were carried out at the 7th and 14th week of high-fat diet (n=17, respectively). At the 23rd week of the high-fat diet, 5 and 4 from these *ApoM^-/-^* and WT mice were sacrificed for the measurement of glucose metabolism and RNA microarray assay. Rest of the mice kept feeding for the detection of AKT phosphorylation.

2.2. Measurement of the Liver Metabolic Profiles {#sec2.2}
------------------------------------------------

The liver tissues of mice were removed immediately and washed in cold PBS, snap-frozen in liquid nitrogen, and stored at -80°C until further analysis. Glucose metabolites were extracted from the liver histiocyte lysate using a modified version of the Bligh and Dyer's method \[[@r32]\]. Targeted metabolite profiling was performed on an exion ultra-performance liquid chromatography system (UPLC) coupled with Sciex 6500 Plus Qtrap (Sciex) as described previously \[[@r33]-[@r35]\].

2.3. Microarray Analysis for Differentially Expressed mRNAs {#sec2.3}
-----------------------------------------------------------

The mouse GeneChip® Clariom™ D Array was employed to investigate the liver gene expression profiles of *ApoM^-/-^* mice, which was purchased by Genechem Co., Ltd. This array provides comprehensive coverage of the mouse genome in a cartridge array format designed for use with the GeneChip® Scanner 3000 7G series. The raw microarray data were applied to the Genespring GX predictor algorithm (Santa Clara) for analysis. The qualified data were normalized by the RMA algorithm and subsequently log-transformed followed by median-subtraction \[[@r36]\]. The gene expression data were processed with the unpaired *t*-test in order to identify the differentially expressed genes and the false discovery rate (FDR) was calculated by the Benjamini-Hochberg method \[[@r37]\]. The genes were regarded as differentially expressed when their *P*-value was less than 0.05 and their fold change was higher than 1.2.

2.4. Glucose Measurements and Insulin Tolerance Test {#sec2.4}
----------------------------------------------------

After 14 weeks of high-fat diet, the *ApoM^-/-^* and WT mice (n=17) were subjected to fasting for 5 h and then injected with insulin (Humulin R, 0.5 U/kg body weight; Lilly) intraperitoneally in order to analyze insulin tolerance. The tail blood glucose levels were measured prior to the administration of insulin, and at 15, 45, 60, 90, 120, 150 and 180 min following the administration of insulin using a glucose monitor device (Johnson & Johnson, USA).

2.5. Western Blotting {#sec2.5}
---------------------

The total protein of the murine muscle, liver and adipose tissues was prepared using the E.Z.N.A DNA/RNA/Protein Isolation Kit (Omega). Western blotting was performed using the following antibodies: anti-AKT (cat. no. 4691; Cell Signaling Technology), anti-phospho-AKT (cat. no. 4060; CST); anti-tubulin (cat. no. ab6160; Abcam); anti-β actin (cat. no. 7077; CST).

2.6. Statistical Analysis {#sec2.6}
-------------------------

The data are shown as mean ± SEM. The differences between the two groups were evaluated using an unpaired Student\'s *t*-test. The statistical differences in the volcano map were assessed with the Tukey\'s HSD test. The scale bar in the heat map indicated the Z-score of the transformed and normalized data corresponding to the concentration of the metabolites. All the calculations were performed using GraphPad Prism 8.0 (GraphPad Software, Inc.). *P* values less than 0.05 were used for significant differences.

3. RESULTS {#sec3}
==========

3.1. Metabolite Profile of Glucose Metabolism in *ApoM^-/-^* Mice {#sec3.1}
-----------------------------------------------------------------

(**a**) Blood glucose levels of *ApoM^-/-^* and WT mice after 23-week high-fat diet (n=4 and 5, Student\'s *t* test, \**p*\<0.05). (**b**) Volcano map of glucose-related metabolite changes in liver extracts of *ApoM^-/-^* mice after 23 weeks of high-fat diet (n=4 and 5). The volcano map shows both the *p*-value and the multiples of each variable. Variables that exceed the set threshold are marked (red plots). (Tukey HSD, *p*\<0.05). (**c**) Heat map of glucose-related metabolite changes. The red color and blue color indicate high and low level, respectively.(**d**) % change of glucose-related metabolites in *ApoM^-/-^* mice *vs* WT. (n=4 and 5). % change = 100 × (up-fold change - 1) or 100 × (1- down-fold change). (Student\'s *t-*test, \**p*\<0.05, \*\**p*\<0.01). (*A higher resolution / colour version of this figure is available in the electronic copy of the article*).

A total of 5 and 4 *ApoM^-/-^* and WT mice were selected respectively for this analysis. The mice were fed a high-fat diet for 23 weeks. The blood glucose level of the *ApoM^-/-^* mice was higher than that of the WT mice (Fig. **[1a](#F1){ref-type="fig"}** and **1b**) indicated that erythrose-4-phosphate, ribulose-5-phosphate and phosphoenolpyruvate (red plots) exceeded the threshold (*P*\<0.05 and Fold change\>1). The data in [Fig. (**1c** and **d**)](#F1){ref-type="fig"} provided an overview of the metabolite changes in the liver tissues of the *ApoM^-/-^* mice. The majority of the metabolites from the 16 classes of compounds that were detected by UPLC exhibited lower levels in the *ApoM^-/-^* mice. These were mainly involved in glycolysis, glucuronidation, pentose-phosphate pathway and nucleic acid metabolism. In particular, we focused on the 6 classes of metabolites with statistically significant changes. These were glucose, glucose-6-phosphate (G6P), ribose, ribulose-5-phosphate, erythrose-4-phosphate and adenosine monophosphate (AMP).

3.2. Microarray Profiling of mRNAs in *ApoM^-/-^* Mice {#sec3.2}
------------------------------------------------------

The mouse GeneChip® Clariom™ D Array was applied to profile the expression levels of mRNAs in *ApoM^-/-^* and WT mice following 23 weeks of a high-fat diet. The quality of microarray data was validated and the Volcano and Scatter plots are depicted in [Fig. (**2a** and **b**)](#F2){ref-type="fig"}, respectively. The volcano plot was used for assessing gene expression variation between *ApoM^-/-^* and WT mice. The scatter plot exhibited the distribution of the signals between *ApoM^-/-^* and WT mice in the Cartesian coordinate plane. The hierarchical clustering of the genes produced a dendrogram and the heat map was used for analyzing and visualizing microarray data \[[@r38]\] (Fig. **[2c](#F2){ref-type="fig"}**).

A total of 1,134 and 950 from 2,084 mRNAs were categorised as high-expressed and low-expressed (*ApoM^-/-^* vs WT), respectively. The top 10 differentially expressed genes between the two groups are listed in Table **[1](#T1){ref-type="table"}**. The data suggested that the expression levels of the mRNAs selected in the *ApoM^-/-^* mice differed from those in the WT mice.

GO function annotation indicated that the enriched differentially expressed genes were mainly related to the following biological processes: cellular response to stress, organic substance and positive regulation of gene expression. The GO category of the cellular components was closely associated with extracellular space, intracellular vesicle and neuron. In addition, the differentially expressed genes were significantly enriched in the processes involving adenyl nucleotide binding, identical protein binding and poly-A RNA binding in the GO molecular function module (Fig. **[3a](#F3){ref-type="fig"}**).

Pathway analysis revealed the metabolic pathways undergoing significant changes between the two groups. The data indicated that the differentially-expressed mRNAs were mainly associated with the following signaling pathways: adipocytokine signaling, apoptosis and maturity-onset diabetes of the young (Fig. **[3b](#F3){ref-type="fig"}**). The genes involved in the glucose metabolism pathway are summarized in Table **[2](#T2){ref-type="table"}**.

3.3. ApoM Improves Insulin Resistance via an AKT-Dependent Mechanism {#sec3.3}
--------------------------------------------------------------------

The *ApoM^-/-^* and WT mice were fed a high-fat diet for a total of 34 weeks. After 7 weeks of the high-fat diet, the blood glucose levels were significantly higher in *ApoM^-/-^* mice following 5 h of fasting (Fig. **[4a](#F4){ref-type="fig"}**). The weight loss of the mice was noted in the *ApoM^-/-^* group at the end of the 29th week compared with that noted in the WT group  (Fig. **[4b](#F4){ref-type="fig"}**). After 14 weeks of the high-fat diet, an insulin tolerance test was performed to evaluate the modulation of insulin sensitivity. Significant differences were observed between the *ApoM^-/-^* and the WT mice at 45 min and 60 min, respectively (Fig. **[4c](#F4){ref-type="fig"}**). The sensitivity to insulin was reduced when *ApoM* was knocked out (Fig. **[4c](#F4){ref-type="fig"}**). The AKT phosphorylation levels in the skeletal muscle and adipose tissues were attenuated in *ApoM^-/-^* mice following insulin injection (Fig. **[4d](#F4){ref-type="fig"}** and **e**) after 34 weeks of the high-fat diet.

4. DISCUSSION {#sec4}
=============

Currently, insufficient evidence has been provided with regard to the association of *ApoM* deficiency with glucose metabolism. In the present study, the data indicated that following a period of high-fat feeding, the blood glucose levels of the *ApoM^-/-^* mice were significantly higher than those of the WT mice, which was consistent with previous studies \[[@r39]\]. This indicated that in the presence of risk factors for diabetes, apoM demonstrated a protective effect on blood glucose levels. A combination of metabolite profile and microarray analysis in the histiocyte lysate from the mouse liver tissues demonstrated that apoM affected glucose metabolism. Metabolomics is a novel biomedical field used to identify the overall metabolic changes in living organisms \[[@r40]\]. This method provides new insights into the study of diabetes and diabetic complications \[[@r41]\]. Since apoM has been notably studied in liver tissues due to its production by hepatocytes \[[@r42], [@r43]\], the changes of the glucose metabolites in *ApoM^-/-^* mice liver were analyzed by metabolomics. Heat map analysis revealed the presence of differentially expressed metabolites, and the results indicated that the majority of these metabolites were reduced in the liver tissues of the *ApoM^-/-^* mice. Moreover, significant differences were noted in 6 out of the total 16 metabolites, as demonstrated by the unpaired Student's *t*-test. The glucose levels in *ApoM^-/-^* mice were higher in the blood and lower in the liver tissues. It was hypothesized that this effect may be attributed to the impaired glucose uptake function of *ApoM^-/-^* liver cells that leads to the accumulation of glucose in the peripheral blood. In addition, G6P is produced by phosphorylation of glucose on the sixth carbon \[[@r44]\]. The decrease in glucose utilization subsequently results in a decrease of G6P formation \[[@r45]\]. Three differential metabolites, namely ribulose-5-phosphate, erythrose-4-phosphate and phosphoenolpyruvate were screened by the Tukey HSD using the following thresholds: *P*\<0.05 and fold change\>1. The metabolic profile of phosphoenolpyruvate resembled that of G6P, which was also an intermediate product in glycolysis \[[@r46]\]. Ribulose-5-phosphate and erythrose-4-phosphate were intermediate metabolites in the pentose phosphate pathway (PPP) \[[@r47]\]. Their reduction was evident along with the reduction in ribose, suggesting that apoM affected the regulation of the PPP. The PPP is a surrogate pathway of glycolysis and is critical for the synthesis of ribonucleotides comprising a major source of NADPH production \[[@r47]\]. The dehydrogenation from G6P to ribulose 5-phosphate is the first step of the PPP and therefore it is highly possible that the reduction of G6P may trigger the attenuation of the PPP \[[@r48]\]. The present study revealed that the knockout of *ApoM* resulted in the alteration of the glucose metabolite levels in the liver tissues, which subsequently caused glucose-lipid metabolism disorder and eventually led to a series of metabolic diseases, such as diabetes.

In order to further understand the mechanism of these metabolic disorders, bioinformatic analysis was applied to compare differentially expressed mRNAs in the liver tissues

of both *ApoM^-/-^* and WT mice. Volcano and scatter plots were used for assessing gene expression variations between the two groups. Hierarchical clustering analysis demonstrated systematic variations in the expression levels of mRNAs among the samples. The differentially expressed genes were ranked based on the fold change and were listed as the top 10 genes in Table **[1](#T1){ref-type="table"}**. The first gene in the list was *Onecut1* (*one cut homeobox 1*), also known as *Hnf-6* (*hepatocyte nuclear factor 6*), which is a transcriptional activator of several genes, associated with various regulatory pathways influencing glucose metabolism, cholesterol metabolism, bile acid biosynthesis, as well as the synthesis and transport of serum carrier proteins \[[@r49], [@r50]\]. HNF-6 is also an important regulator of pancreatic endocrine development \[[@r51]\]. Continuous expression of HNF-6 in mature β-cells leads to loss of pancreatic function and apoptosis \[[@r52]\]. Another differentially expressed gene, namely *Gpcpd1* (*Glycerophosphocholine phosphodiesterase 1*) is also involved in glycerophosphocholine hydrolysis and in skeletal muscle development \[[@r53]\]. The data indicated that the *ApoM* gene defect affected the expression of these differentially expressed genes associated with glucose metabolism. The expression of these genes will be verified by qPCR in the next study thus further exploring their relationship with apoM. GO and KEGG pathway analyses of differentially expressed mRNAs further provided additional information regarding glucose metabolism \[[@r54]\]. All of the differentially expressed mRNAs were utilized for the GO analysis and the results were summarized in four pathways associated with glucose metabolism (Table **[2](#T2){ref-type="table"}**). The defect in the *ApoM* gene expression affected the process of the pentose and glucuronate interconversions, which was consistent with the data on glucose metabolism derived from the metabolomic studies. It has been reported previously that type 2 diabetes is associated with lower plasma apoM levels \[[@r55]\]. Moreover, serum apoM levels were suggested as a marker for the mature onset diabetes of the young monogenic forms of diabetes \[[@r17]\]. The results of the present study confirmed genetically that apoM was indeed associated with MODY and that it may be involved in islet cell development via *onecut1*. These findings provided a possible explanation for the different glucose metabolism profiles noted by different mouse genotypes following high-fat diets.

The most important pathway discovered was AKT signaling pathway. Enrichment analysis indicated that the AKT pathway in *ApoM^-/-^* mice differed from that in WT mice. A previous study has shown that insulin can regulate skeletal muscle and adipose metabolism by promoting glucose transport, glycogen synthesis and protein synthesis by the AKT pathway \[[@r56]\]. Therefore, it was supposed that apoM affected glucose metabolism through AKT pathway. AKT phosphorylation levels were further validated in different tissues. Defects in insulin action within muscle and adipose tissues are common features of insulin resistance \[[@r57], [@r58]\]. Therefore, insulin was injected into mice as a trigger for observing the activation level of AKT in different tissues \[[@r59]\]. According to the results of the present study, high blood glucose levels and low body weight in *ApoM^-/-^*mice suggested that the absence of apoM increased the risk of developing diabetes in mice. Kurano *et al* reported that overexpression of apoM did not significantly ameliorate insulin sensitivity in WT mice \[[@r39]\], whereas the insulin tolerance test used in the present study suggested that insulin sensitivity was impaired in *ApoM^-/-^* mice. The phosphorylation levels of AKT in muscle and adipose tissues of *ApoM^-/-^* mice were significantly diminished in response to insulin stimulation compared with those noted in WT mice (Fig. **[4d](#F4){ref-type="fig"}** and **e**). Although three differentially-expressed genes overlapped in the AKT pathway according to microarray analysis (Table **[2](#T2){ref-type="table"}**), no significant difference in AKT activation was noted following injection of insulin in the liver tissues. It was assumed that this effect was noted due to the liver being a secondary insulin-sensitive organ \[[@r60]\]. The underlying mechanism requires further investigation.

Further human, animal and cellular experiments are required to substantiate the effects of apoM on glucose metabolism as well as to delineate the mechanisms underlying the association of apoM and T2D, and therefore establish its clinical relevance.

CONCLUSION
==========

In conclusion, the results of the metabolite profile and microarray analysis indicated the presence of glucose metabolism disorders in *ApoM^-/-^* mice, notably insulin resistance, which eventually resulted in the development of T2D. The *in vivo* experiments of the present study indicated that apoM possibly augmented insulin sensitivity via an AKT-dependent mechanism.
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![Glucose related metabolite changes in liver extracts of *ApoM^-/-^* mice.](EMIDDT-20-771_F1){#F1}

![Screening and clustering of differentially-expressed mRNA between *ApoM^-/-^* and WT mice. (**a**) Volcano Plot, which demonstrated the distribution of the differentially expressed genes between *ApoM^-/-^* and WT mice. The X-axis represents the logarithm conversion of the fold difference to base 2 and the Y-axis represents the logarithm conversion of the correct significant levels to base 10. The red color represents all the probes with fold difference \>1.2 at a significant level of *p*\<0.05. (**b**) Scatter plot, which exhibited the distribution of the signals between *ApoM^-/-^* and WT mice in a Cartesian coordinate plane. The X-axis represents the WT group, and the Y-axis represents the *ApoM^-/-^* group. The ordinate value and the abscissa of each spot represent the expression values of one probe in two groups. Red represents the up-regulated genes in *ApoM^-/-^* group, green represents the up-regulated genes in the WT group, and plots between green parallel lines represent insignificant differentially-expressed genes. (**c**) Clustering diagram of the differentially-expressed RNAs shared in two groups. The color scale represents the different expression of genes from low-to-high, with green representing down-regulated and red representing up-regulated. (*A higher resolution / colour version of this figure is available in the electronic copy of the article*).](EMIDDT-20-771_F2){#F2}

![The Gene Ontology terms and KEGG pathway enrichment of *ApoM^-/-^* and WT mice. (**a**) GO-BP: Biological process of gene ontology terms. GO-CC: Cellular component of gene ontology terms. GO-MF: Molecular function of Gene Ontology terms. (**b**) KEGG pathways. FDR = false discovery rate. (*A higher resolution / colour version of this figure is available in the electronic copy of the article*).](EMIDDT-20-771_F3){#F3}

![ApoM improves insulin resistance via AKT-dependent mechanism. (**a**) Blood glucose levels of *ApoM^-/-^* and WT mice at the 7th week (n=17). (**b**) Bodyweight comparison of *ApoM^-/-^* and WT mice at the 29th week. (*ApoM^-/-^*: n=16, WT: n=17). (**c**) Insulin tolerance test at the 14th week. Insulin (0.5U/kg body weight) was administered intraperitoneally (n=17). (**d** & **e**) Western blot analysis of phosphorylated Akt (p-Akt) and total Akt (Akt) with homogenates of skeletal muscle (n=15 or 17), liver (n=16) and adipose tissue (n=7 or 8) at the 34th week. The mice were subjected to a 5 h fast, followed by an intraperitoneal injection of 0.5U/kg insulin 30 min prior to euthanization. (*A higher resolution version of this figure is available in the electronic copy of the article*).](EMIDDT-20-771_F4){#F4}

###### 

Top 10 differentially expressed genes between *ApoM^-/-^* and WT mice.

  **Gene Symbol**   **Fold Change**   **ANOVA *p*-value**   **Description**
  ----------------- ----------------- --------------------- ------------------------------------------------------------
  *Onecut1*         3.8037            0.0087                One Cut Homeobox 1
  *Nudt7*           3.1684            0.0046                Nudix Hydrolase 7
  *Gpcpd1*          2.6276            0.0215                Glycerophosphocholine Phosphodiesterase 1
  *Cish*            2.4723            0.0006                Cytokine Inducible SH2 Containing Protein
  *Slco1a4*         2.2923            0.0364                Solute carrier organic anion transporter family member 1A4
  *Saa1*            -4.6466           0.0258                Serum Amyloid A1
  *Saa2*            -4.0098           0.0309                Serum Amyloid A2
  *Slc41a2*         -3.4307           0.0087                Solute Carrier Family 41 Member 2
  *Nnt*             -3.2860           0.0037                Nicotinamide Nucleotide Transhydrogenase
  *Fgl1*            -3.1009           0.0306                Fibrinogen Like 1

###### 

Genes involved in the glucose metabolism pathway.

  **Gene Set Name**                            ***p*-value**   **FDR**   **Genes in Overlap**
  -------------------------------------------- --------------- --------- ----------------------
  *Maturity onset diabetes of the young*       0.0000329       0.0026    *pklr*
  *onecut1*                                                              
  *hhex*                                                                 
  *foxa2*                                                                
  *ARAP Pathway (ADP-ribosylation factor)*     0.000302        0.011     *gbf1*
  *cltb*                                                                 
  *kdelr2*                                                               
  *AKT Signaling Pathway*                      0.000557        0.0172    *ikbkg*
  *akt1*                                                                 
  *nfkbia*                                                               
  *Pentose and glucuronate interconversions*   0.00115         0.0243    *ugt2a1*
  *ugp2*                                                                 
  *dhdh*                                                                 

FDR = false discovery rate.

Genes in overlap: differential genes overlap in this pathway.
